• Explore /
  • Poster
  • / Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic <em>BRCA1</em>,<em> BRCA2</em>, or <em>PALB2</em> mutation—ECOG-ACRIN EA2192.

Apollo: A randomized phase II double-blind study of olaparib versus placebo following curative intent therapy in patients with resected pancreatic cancer and a pathogenic BRCA1, BRCA2, or PALB2 mutation—ECOG-ACRIN EA2192.

Abstract Poster

Authors

null

Kim Anna Reiss

University of Pennsylvania, Philadelphia, PA

Kim Anna Reiss , Sung Chul Hong , Anup Kasi , Eileen Mary O'Reilly , Shishir K. Maithel , Xin Yao , Stanley R. Hamilton , Ben Boursi , Michael J. Pishvaian , Samuel J Klempner , Susan M. Domchek , Paul J. Catalano , E. Gabriela Chiorean , Philip Agop Philip , Peter J. O'Dwyer

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2023 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Pancreatic Cancer - Local-Regional Disease

Clinical Trial Registration Number

NCT 04858334

Citation

J Clin Oncol 41, 2023 (suppl 16; abstr TPS4202)

DOI

10.1200/JCO.2023.41.16_suppl.TPS4202

Abstract #

TPS4202

Poster Bd #

507b

Abstract Disclosures

Similar Posters

First Author: Kim Anna Reiss

First Author: Severine Guiu Lahaye

First Author: E. Gabriela Chiorean

First Author: Kim Anna Reiss